Sign inJoin waitlistJoin the waitlist

Alexi Wright

Director, Gynecologic Oncology Outcomes Research · Mass General Brigham

Credentials: · · · ·

History

Mass General Brigham
Present

Dana-Farber Cancer Institute
2006–2008
Internal Medicine
Brigham and Women's Hospital
2003–2006
Harvard School of Public Health
The Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania
1999–2003

Research

Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment
JAMA · 2008 · First of 11 authors · Corresponding · 2,145 citations
Landscape of genomic alterations in cervical carcinomas
Nature · 2014 · 718 citations
Health care costs in the last week of life: associations with end-of-life conversations
Archives of Internal Medicine · 2009 · 717 citations

Ursula Matulonis
33 papers
Nancy Keating
32 papers
Andrea Enzinger
22 papers · 6 as a fellow
Susana Campos
21 papers
Joyce Liu
20 papers
IK
Ingrid Katz
18 papers · 8 as a resident
James Tulsky
17 papers
Neil Horowitz
17 papers
Panagiotis Konstantinopoulos
16 papers
Larissa Meyer
13 papers
Tracy Balboni
13 papers · 8 as a fellow
Carolyn Krasner
12 papers

Grants

Randomized Trial of REVITALIZE: A Telehealth Intervention to Reduce Fatigue Interference Among Adults with Advanced Ovarian Cancer on PARP Inhibitors
National Cancer Institute · R01
Contact PI · $2.1M · Dana-Farber Cancer Inst
2024–2029
Variability in Opioid Prescribing Across the Cancer Care Continuum: A Multi-Level Analysis
National Cancer Institute · R01
PI · $2.2M · Dana-Farber Cancer Inst
2024–2029
BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Cancer - A Multi-Site Randomized Controlled Trial
National Cancer Institute · R01
Contact PI · $2.8M · Dana-Farber Cancer Inst
2023–2028
Passive Data to Improve Outcomes in Advanced Cancer
National Institute of Nursing Research · R21
Contact PI · $459.5K · Dana-Farber Cancer Inst
2019–2022

Clinical trials

BRIDGE-SIC Efficacy Trial
Principal investigator · Recruiting
Dana-Farber Cancer Institute
2026–2028
BOLSTER: Learning New Skills to Thrive
Principal investigator · Recruiting
Dana-Farber Cancer Institute
2025–2028
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Principal investigator · Recruiting
Dana-Farber Cancer Institute
2025–2029
SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care
Principal investigator · Withdrawn
Dana-Farber Cancer Institute
2022–2023